Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683019 · ClinicalTrials.gov registry record · NA
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
A NA study, sponsored by Wave Neuroscience.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT01683019: Completed NA study, sponsored by Wave Neuroscience.
NCT01683019 is a NA study that has completed, run by Wave Neuroscience. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01683019, a NA study, has completed, sponsored by Wave Neuroscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
Primary Outcome
Outcome measured using the Hamilton Depression Rating Scale (HAMD-17) and calculated as percent change in severity score from baseline until the end of the 4th week of treatment. The HAMD-17 scale ranges between 0-54, with higher numbers indicating more severe symptoms. 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates moderate to severe depression.
Interventions
- DEVICE NeoSync EEG Synchronization Therapy
- DEVICE Sham NeoSync EEG Synchronization Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT01683019 record still lists
NCT01683019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which NeoSync EEG Synchronization Therapy is the first listed.
NCT01683019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01683019 about?
NCT01683019 is a clinical study titled "Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression". This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
What is the current status of trial NCT01683019?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2008-06. Estimated completion is 2008-12.
What interventions are being tested in trial NCT01683019?
The interventions under investigation include: NeoSync EEG Synchronization Therapy (DEVICE), Sham NeoSync EEG Synchronization Therapy (DEVICE).
Who is sponsoring clinical trial NCT01683019?
This trial is sponsored by Wave Neuroscience, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01683019's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia